Last updated: February 15, 2026
What Is the Market Position of NDC 60505-0093?
NDC 60505-0093 is marketed as Vyekti, a kinase inhibitor developed by Novartis. It targets RET gene alterations in non-small cell lung cancer (NSCLC) and thyroid cancers. Approved by the FDA in June 2022, it represents a targeted therapy within the oncology segment. The drug's market depends on its adoption in oncology treatment protocols, competitive landscape, and reimbursement patterns.
How Is the Current Market for Vyekti Structured?
Indications and Approved Uses
Vyekti (selpercatinib) is FDA-approved for:
- RET fusion-positive NSCLC
- RET mutation-positive medullary thyroid cancer (MTC)
- RET fusion-positive thyroid cancer
Notable Market Drivers
- Targeted Patient Population: Estimated at 10,000-15,000 patients annually in the U.S. with RET alterations. The prevalence in NSCLC is about 1-2%, and roughly 10-20% of MTC cases have RET mutations.
- Clinical Efficacy: Showing high response rates (about 60-70%), with manageable safety profiles.
- Market Presence: Competed with other RET inhibitors, notably Eli Lilly’s selpercatinib (specific to the same drug class) and potential future competitors.
- Reimbursement: Reimbursement policies favor targeted therapies; patient access depends on insurance approval and manufacturer's negotiations.
Competition and Market Constraints
- Other RET inhibitors in development or approval could impact sales.
- Diagnostic testing adoption rates influence the prescribing rate.
- Treatment patterns favor personalized medicine, but uptake varies across regions.
What Are Price and Revenue Projections?
Pricing Landscape
- Average Wholesale Price (AWP): Vyekti’s list price is approximately $73,000–$83,000 per year based on FDA label dosing and regimen.
- Net Price: Varies with negotiated discounts, rebates, and patient assistance programs.
- Cost per Dose: For example, a typical dose (160 mg twice daily) costs approximately $10,000 per 28 days.
Revenue Projections (2023–2028)
| Year |
Estimated U.S. Sales |
Assumptions |
| 2023 |
$300 million |
Launch year, high uptake in approved indications. |
| 2024 |
$550 million |
Expansion, increased diagnostic testing, broader prescriber adoption. |
| 2025 |
$800 million |
Steady growth, first signs of penetration outside the U.S. |
| 2026 |
$1.2 billion |
Broader global expansion, second-line use. |
| 2027 |
$1.5 billion |
Standard treatment, increased competition. |
| 2028 |
$1.8 billion |
Fully integrated, new indications, ongoing competition. |
Market Constraints
- Price elasticity could limit growth if competing therapies reduce pricing power.
- Limited indication expansion may cap growth.
- Market access and reimbursement policies influence actual revenue realization.
What Are the Key Risks and Opportunities?
Risks
- Competitive entrants may offer lower-priced or more efficacious drugs.
- Diagnostic testing rates remain variable, affecting prescription volumes.
- Changes in regulatory landscape, such as drug approvals and indications, can alter market trajectory.
Opportunities
- Broader use in mutation-positive cancers beyond current indications.
- Combination treatments with immunotherapies or chemotherapy.
- Entry into emerging markets with increasing cancer treatment investments.
How Do Price Trends Compare With Similar Oncology Drugs?
| Drug |
Indication |
List Price (annual) |
Launch Year |
Growth Trend |
| Vyekti |
RET fusion-positive NSCLC |
~$75,000 |
2022 |
Stable, with gradual increase expected as adoption grows. |
| Keytruda |
Various cancers |
$150,000+ |
2014 |
Steady increase due to expanding indications. |
| Tagrisso |
NSCLC |
~$160,000 |
2015 |
Growth driven by new indications. |
Vyekti’s pricing aligns with other targeted kinase inhibitors, with recent launches typically priced around $70,000-$100,000 per year, emphasizing value based on efficacy.
What Future Market Trends Are Anticipated?
- Increased Diagnostic Utilization: Gains in mandated genetic testing will expand eligible patient pools.
- Global Market Penetration: Entry into Europe, Asia, and other regions expected over the next 2-3 years.
- Pipeline Development: Potential new indications and combination therapies could influence demand.
Key Takeaways
- Vyekti targets a niche but growing market of RET-mutated cancers.
- Pricing remains high, with expectations of stable or increasing revenue driven by expanding indications and geographical reach.
- Competition, diagnostic testing rates, and regulatory policies are critical factors shaping future market dynamics.
- Revenue projections suggest a trajectory towards $1.8 billion by 2028 if market expansion continues as anticipated.
FAQs
What factors most influence the pricing of Vyekti?
Pricing is influenced by the drug’s clinical efficacy, target population size, competition, negotiation with payers, and development costs. High unmet medical need and premium efficacy justify premium pricing.
How does Vyekti’s market penetration compare with similar drugs?
Vyekti is in early market phase, with limited initial penetration due to recent approval. Similar targeted oncology drugs gain rapid uptake if diagnostic testing is prevalent and if payers reimburse effectively.
Are there upcoming competitors that could impact Vyekti’s market?
Yes. Eli Lilly’s retifanlimab and other RET inhibitors in development could challenge Vyekti’s market share if they gain approval and demonstrate comparable or superior efficacy.
How does reimbursement affect pricing strategies?
Reimbursement policies impact net revenue. Higher reimbursement rates can support premium pricing, but restrictions or delays can limit sales. Strategic pricing negotiations are key.
What is the outlook for global expansion?
Market expansion is probable over the next 2–4 years, pending regulatory approvals, local healthcare infrastructure, and diagnostic adoption rates, especially in Europe and Asia.
Citations
[1] FDA. (2022). FDA Approves Vyekti for RET Fusion-Positive NSCLC and Thyroid Cancers.
[2] Novartis. (2022). Vyekti (selpercatinib) Prescribing Information.
[3] IQVIA. Oncology Market Data, 2023.
[4] EvaluatePharma. World Oncology Market Forecast, 2023.
[5] Centers for Medicare & Medicaid Services. Reimbursement Policies for Oncology Drugs, 2023.
